🔎 Trials Near Me

Beranda › Mielofibrosis › Alabama

Uji klinis Mielofibrosis di Alabama

7 studi untuk Mielofibrosis mencari peserta di lokasi di Alabama.

Kota di Alabama

Teks studi resmi (Bahasa Inggris)

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

  • University of Alabama, Birmingham
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04176198

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  • University of Alabama At Birmingham, Birmingham
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT07441694

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

  • University of Alabama at Birmingham, Birmingham
Menerima pesertaFase 1
4 Weeks – 75 Years · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT06047886

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

  • University of Alabama Birmingham, Birmingham
Menerima pesertaFase 2
Usia 18 hingga 66 · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06859424

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Birmingham
  • Massive Bio SYNERGY-AI site, Mobile
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  • UAB Hospital, Birmingham
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2025 · NCT06479135

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

  • University of Alabama at Birmingham, Birmingham
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Feb 2023 · NCT05280509

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.